Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS
Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS
Enrolling by invitation · NCT07743268 · Registry updated 2026-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS | Nutritional and Metabolic Diseases, TDP-43 proteinopathy, amyotrophic lateral sclerosis, central nervous system disorder, metabolic disease, motor neuron disorder, nervous system disorder, neurodegenerative disease, neuromuscular disease, proteostasis deficiencies, spinal cord disorder | Enrolling by invitation | Phase 1 / Phase 2 | 2026-08-03 | NCT07743268 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Columbia University | 375 |
| n-Lorem Foundation | 18 |
| Washington University School of Medicine | 475 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Columbia University, Irving Medical Center | New York | United States | 3 |
| Washington University | St Louis | United States | 182 |